London, 17 March 2015 – Pressing unmet medical needs have resulted in the growth of the HER-2 Positive Breast Cancer Market in the US, which is expected to post a CAGR of 12.65 percent from 2014-2019, says research firm TechNavio.
About the Report
According to the latest report by TechNavio, the current treatment options for cancer are associated with serious side effects. Targeted therapies are costly, but the evidence for the efficacy of targeted therapies, such as HER2-targeted trastuzumab therapy, for patients with treatment-resistant metastatic breast cancer is also increasing.
“HER-2 positive breast cancer is aggressive and palliative therapies help increase the survival rate of patients,” says Faisal Ghaus, Vice President of TechNavio.
“Drug makers in this market have the opportunity to design and develop a drug that can cater to the unmet needs in the market.”
The new TechNavio report also emphasizes the emergence of targeted and combination therapies, which cause fewer side effects than conventional chemotherapies. Cancer involves the disruption of multiple mechanisms, therefore, combination therapies which target distinct mechanisms are highly efficacious in treating cancer.
“Drugs that target HER-2 receptors like Herceptin and Kadcyla can be administered as monotherapy or in combinations,” says Ghaus.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2019
Market Growth Drivers:
- Increase in Prevalence of Breast Cancer
- For a full detailed list, view our report.
Market Challenges:
- Poor Diagnosis and Screening
- For a full detailed list, view our report.
Market Trends:
- Increase in Awareness
- For a full detailed list, view our report.
Key Vendors:
- Celgene Corp.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
Other Prominent Vendors:
- Bristol-Myers Squibb
- DARA BioSciences
- Eisai
- Hospira
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
